Nestled in the heart of Minnesota farm country, Aurora Pharmaceutical is proving that high-quality, FDA-approved veterinary medicines can still be made in the USA, and they don’t have to break the bank.

Founded in 2007 by a pair of veterinarians, Aurora has carved out a unique space in the animal health industry by focusing on cost-effective, FDA bioequivalent medications for livestock and companion animals. With a research and manufacturing model built around speed, safety and affordability, the company is transforming access to animal health care without compromising on quality.

Born from Veterinary Insight

Aurora was not built by a multinational corporation or a private equity firm. It was founded by veterinarians who understood, firsthand, the barriers that rising drug costs posed to clinics, producers and pet owners alike.

“The veterinary perspective informs every decision we make,” says Dr. Mike Strobel, CEO of Aurora Pharmaceutical. “We understand what practitioners and producers need in the field because we’ve lived it.”

This practitioner-led approach influences everything from product development and packaging to marketing support and pricing. While large players in the industry often prioritize blockbuster innovations, Aurora focuses on meeting real-world needs with safe, effective generic bioequivalent alternatives to brand-name medications that are often priced out of reach for smaller operations.

FDA-Approved and Bioequivalent: What That Means

Aurora specializes in the development of FDA-approved generic – or “bioequivalent” – veterinary medicines. These products match the brand-name counterparts in active ingredients, dosage, safety and therapeutic effect but are often available at a significantly reduced price.

Each of Aurora’s generic products undergoes a rigorous FDA approval process through the Abbreviated New Animal Drug Application (ANADA) pathway. This ensures the product delivers the same therapeutic results as the reference brand while adhering to the highest manufacturing standards.

This isn’t about cutting corners. It’s about expanding access. In many cases, producers and veterinarians opt to reduce dosing frequency or delay treatment due to cost concerns. Aurora’s generics help remove that financial pressure and enable timely, full-strength care.

Manufacturing in Minnesota: Why 'Made in the USA' Matters

Unlike many competitors, Aurora doesn’t rely on outsourced production. All of Aurora’s products are manufactured and packaged in its Northfield, Minnesota, facility. This control over the supply chain ensures quality and consistency from start to finish.

“Our domestic production gives us real-time oversight,” says Strobel. “It means we can react faster to changes in demand, maintain tighter quality control and support American jobs all while avoiding the same supply chain issues that have plagued the industry in recent years.”

Manufacturing in the U.S. also means greater transparency. Aurora is fully compliant with FDA and GMP regulations and is regularly inspected to maintain its certifications. Every step, from raw ingredient sourcing to bottling, follows current Good Manufacturing Practices, the gold standard for quality assurance.

Efficiency as a Competitive Advantage

In a highly regulated industry, speed matters. While many pharmaceutical companies spend four to six years bringing new generics to market, Aurora’s lean structure and focused mission allow it to cut that timeline nearly in half.

On average, Aurora develops and launches new products in just two to two-and-a-half years. That speed isn’t about rushing; it’s about cutting bureaucratic waste and focusing on what matters: efficacy, safety and customer needs.

By doing so, the company helps close critical gaps in the market and gives veterinarians access to cost-effective solutions more quickly, something especially important in large-animal and production medicine, where economics are always front of mind.

A Pricing Model That Levels the Playing Field

Affordability is often a moving target in animal health care, especially when pricing favors volume. But Aurora intentionally avoids that trap. The company follows a “level pricing” model, ensuring that small clinics pay the same fair rate as larger practices or corporate buyers.

“We don’t believe you should have to be a huge distributor or national chain to get access to quality medicines,” says Strobel. “Fair pricing should be available to every veterinarian and producer, no matter the size of their operation.”

This commitment to equity extends beyond pricing. Aurora also supports its customers with direct sales teams, educational resources and marketing assistance. Their approach is refreshingly relationship-driven – more partnership than transaction.

Giving Back Through Education

Aurora’s investment in the veterinary community doesn’t stop at products. The company actively supports future veterinarians through its national scholarship program, awarding more than $90,000 in scholarships to third-year veterinary students in 2025 alone.

By lifting some of the financial burden from students (many of whom graduate with six-figure debt), Aurora is contributing to the long-term strength and diversity of the profession. And because those scholarships are awarded to students pursuing both large- and small-animal practice, the benefits extend across the entire veterinary landscape.

Looking Ahead: Innovation with Integrity

With a strong foundation, loyal customer base and a growing national footprint, Aurora is poised for continued growth. But don’t expect them to become another faceless conglomerate.

“Our focus will always be on serving veterinarians and producers,” Strobel says. “We believe in science-backed solutions, in local manufacturing and in making quality care affordable.”

As the veterinary profession continues to evolve, with pressures from corporate consolidation, rising costs and global supply chain instability, Aurora’s approach feels especially relevant. It’s a model built not just for growth, but for resilience.

And in a world where so much is uncertain, that kind of grounded, American-made reliability is something everyone can appreciate.

What Is a 'Bioequivalent' Veterinary Medicine?

Bioequivalent drugs are FDA-approved generics that contain the same active ingredients, strength, dosage form and route of administration as their brand-name counterparts. They are rigorously tested to ensure they provide the same therapeutic effect, offering veterinarians and producers a reliable, lower-cost alternative without sacrificing quality.